丰公司的季度亏损超过分析师预期, Annexon beats analyst expectations with a $0.28 quarterly loss.

尽管公众普遍预计全年亏损0.96美元, 但安克森公司的季度亏损超过分析师们的预期. Annexon beat analyst expectations with a $0.28 quarterly loss, though consensus estimates forecast a $0.96 full-year loss. 分析师给生物技术公司一个"中等购买"评级,目标是17美元, 而内部人士最近卖掉了股票. Analysts gave the biotech a "Moderate Buy" rating with a $17 target, while insiders sold shares recently. 该公司专注于补充向治疗,在神经退行性疾病的第二阶段试验中推进ANX005. The company focuses on complement-targeted therapies, advancing ANX005 in Phase 2 trials for neurodegenerative diseases.